We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Automated Immunoassay for Testosterone Evaluated

By LabMedica International staff writers
Posted on 21 Feb 2011
A new electrochemiluminescence testosterone immunoassay has been evaluated and compared with existing methods. More...


The competitive immunoassay uses high affinity sheep monoclonal testosterone-specific antibody, which is complexed with the serum samples, and after processing the chemiluminescent emissions are measured by a photomultiplier.

Scientists at the University Medical Center Göttingen, (German), collaborated with others medical centers to evaluate the second-generation electrochemiluminescence assay and compare it to a validated assay. The scientists investigated the within-run precision, total precision, and method comparisons to the former immunoassay and the liquid chromatography tandem mass spectrometry (LC-MS/MS) assay. They were also interested in establishing reference intervals for adults and children. Special attention was paid to females with acute renal failure.

The within-run precision and total precision were determined using five different and site-specific human serum pools and two quality control samples. The within-run imprecision ranged from 12.8 μg/L, (0.9%) to 0.23 μg/L (5.2%), and total imprecision ranged from 12.7 μg/L (2.2%) to 0.22 μg/L (8.5%). The recovery according to quality control sample target values was 2.51 μg/L (95.4%) at one center, and 6.30 μg/L (103.6%) at another.

The new Elecsys Testo II assay (Roche Diagnostics GmbH, Mannheim, Germany) was compared against the former Roche Elecsys Testo assay and to a validated LC-MS/MS assay. Precision was improved especially at concentrations below 2.0 μg/L when compared to the former Elecsys Testo assay. The measuring range of 0.12 μg/L to 15.0 μg/L fulfils clinical needs. The new Elecsys Testo II assay demonstrated superior agreement in comparison to the validated LC-MS/MS method indicating an improved specificity.

Surprisingly, some high testosterone concentrations were found in samples from female patients, as confirmed by LC-MS/MS, as these individuals were suffering from polycystic ovary (PCO) syndrome or even androgen-producing tumors. The authors noted that overestimated values, especially with the former Elecsys immunoassay as compared to LC-MS/MS, were found to be from patients suffering from end-stage renal disease undergoing hemodialysis. The study was published in February 2011, in Clinical Biochemistry.

Related Links:
University Medical Center Göttingen
Roche Diagnostics



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automatic Hematology Analyzer
LABAS F9000
New
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: A diagnostic test can distinguish patients with head and neck squamous cell carcinoma who can be cured with surgery alone (Photo courtesy of University of Turku)

Novel Diagnostic Tool to Revolutionize Treatment Guidance of Head and Neck Cancer

Head and neck squamous cell carcinoma (HNSCC) is a solid tumor type commonly treated with surgery. However, there has been no clinically available method to determine which patients can be cured with surgery... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Microbiology

view channel
Image: The groundbreaking salmonella antimicrobial resistance prediction platform has demonstrated 95% accuracy (Photo courtesy of Yujie You et al., DOI: 10.1016/j.eng.2025.01.013)

New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance

Antimicrobial-resistant Salmonella strains are a growing public health concern due to the overuse of antimicrobials and the rise of genetic mutations. Accurate prediction of resistance is crucial for effective... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.